Clinical trial
A Phase 2 Randomized, Placebo-Controlled Study in Mainland China to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218
NCT04507269 is registered in ClinicalTrials.gov with Brii Biosciences Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Randomized, Placebo-Controlled Study in Mainland China to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218
- Lead sponsor
- Brii Biosciences Limited
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 18, 2020
- Completion date
- September 30, 2021
- Enrollment
- 21 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.